• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
cnb1439_3rs-project_nav-ad_v1
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

CN Bio appoints Lydia Seymour as VP People and Culture to further strengthen leadership team

June 27, 2024

Key appointment to support continued UK and US team expansion

CN Bio, a leading provider of single- and multi-organ microphysiological systems, today announced the appointment of Lydia Seymour as Vice President of People and Culture.

In this role, Lydia will work alongside the Company’s management team, providing guidance and support across recruitment and employee wellbeing, in addition to ensuring the implementation of robust professional development plans for CN Bio’s growing global team, and driving new initiatives to enhance workplace culture.

Lydia’s appointment follows several crucial senior hires made over the last year across both the UK and US in response to an ongoing surge in demand for new alternative methodologies (NAMs) such as the Company’s PhysioMimix® Organ-on-a-chip (OOC) range of microphysiological systems (MPS). Working with CEO, Dr Paul Brooks, and the Company’s leadership team, Lydia will be responsible for leading internal initiatives to foster collaborations and a supportive workplace culture, ensuring all necessary recruitment and development systems are embedded as the Company continues to execute its global expansion strategy following the $21M first close of its Series B investment round in April 20241.

Lydia is a seasoned professional in HR and people management within the life science industry. Throughout her career, she has supported commercial, R&D, and corporate teams globally, particularly specializing in the US and APAC markets. Lydia has held senior leadership positions at companies including Abcam, TTP Labtech, and Fluidigm Corporation, where she successfully built high-performing people functions and led the design and implementation of development programmes, reward and talent management strategies. Most recently, Lydia was VP of Human Resources at Evonetix, during which time she oversaw the creation of the people systems and processes required to support the Company’s growing team.


Paul Brooks | Lydia Seymour

Dr Paul Brooks, CEO, CN Bio, commented:

“We are extremely proud here at CN Bio to have built such a credible and professional team, who are helping to realise the full potential of Organ-on-a-chip technology to revolutionize drug discovery and development.”

He continued: “At such a pivotal time in CN Bio’s development, Lydia’s expertise in overseeing thorough strategies to ensure effective recruitment and training, as well as fostering inclusive and supportive company culture will be crucial as our team continues to expand globally and underscores our commitment to investing in people as the foundation of our business growth and innovation.”


lydia | Lydia Seymour

Lydia Seymour, Vice President of People and Culture, CN Bio, said:

“CN Bio’s innovative PhysioMimix OOC range of MPS hold great promise to transform how we approach drug discovery, enabling us to bring more effective therapies to market, faster. I look forward to harnessing my expertise in people management, working alongside Paul and the team to implement effective strategies that empower our talented team members to continue to innovate, and prepare the Company for global expansion so that we can continue to meet the needs of our customers.”


References

  1. CN-Bio raises 21 Million Investment

Category iconPress releases Tag iconCN Bio Team,  New Starter

Primary Sidebar

Other recent news

  • Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies July 15, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research July 7, 2025
  • CN Bio to participate in 3Rs Collaborative-lead project with FDA to build confidence in Liver MPS for DILI June 25, 2025
  • CN Bio introduces cross-species DILI services to enhance in vitro to in vivo extrapolation during preclinical drug development June 10, 2025
  • CN Bio expands access to OOC solutions for APAC customers with distributor agreement in South Korea May 20, 2025

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies July 15, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research July 7, 2025
  • CN Bio to participate in 3Rs Collaborative-lead project with FDA to build confidence in Liver MPS for DILI June 25, 2025
Cyber Essentials Logo